Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Yoshihiro Shirai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4907-0101; OpenAlex author ID A5101288864, A5101428121. Sources: OpenAlex.

Their work

Papers
52 (first author 14, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers · 2018: 4 papers · 2019: none · 2020: 1 paper · 2021: 6 papers · 2022: 4 papers · 2023: 5 papers · 2024: 5 papers · 2025: 12 papers · 2026: 7 papers

Papers 50 of 52

  1. Number of Liver Metastases Stratifies Prognosis in Synchronous Metastatic Pancreatic Cancer. Co-author DOI 10.1002/wjs.70666↗
  2. The Goddard score for emphysema predicts the postoperative prognosis in pancreatic cancer. Co-author DOI 10.1007/s00595-025-03188-7↗
  3. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… Co-author DOI 10.1007/s00595-026-03344-7↗
  4. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  5. Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-026-20340-w↗
  6. ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-026-20399-5↗
  7. Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.21873/cdp.10600↗
  8. Abdominal aortic calcification volume as a preoperative prognostic predictor for pancreatic cancer. Co-author DOI 10.1007/s00595-024-02882-2↗
  9. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… Co-author DOI 10.1007/s00595-025-03050-w↗
  10. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. First author DOI 10.1007/s00595-025-03088-w↗
  11. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. Co-author DOI 10.1016/j.suronc.2024.102179↗
  12. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… Co-author DOI 10.1016/j.suronc.2025.102270↗
  13. The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002416↗
  14. Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. Co-author DOI 10.1097/mpa.0000000000002441↗
  15. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Adva… Co-author DOI 10.1177/00031348241272420↗
  16. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. First author DOI 10.1177/00031348241278021↗
  17. A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Tri… First author DOI 10.1371/journal.pone.0325667↗
  18. Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery. Co-author DOI 10.21873/anticanres.17618↗
  19. [Conversion Surgery for Pancreatic Cancer]. Co-author PMID 39957218↗
  20. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-024-03315-x↗
  21. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.01.003↗
  22. The prognosis-based classification model in resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2024.102035↗
  23. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. First author DOI 10.21873/anticanres.16968↗
  24. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17229↗
  25. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-023-08206-3↗
  26. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  27. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1177/00031348231204912↗
  28. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. Co-author DOI 10.21873/anticanres.16150↗
  29. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. First author DOI 10.21873/anticanres.16599↗
  30. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  31. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer durin… Co-author DOI 10.1007/s12032-021-01625-4↗
  32. Inhibition of lysosomal acid β-glucosidase induces cell apoptosis via impairing mitochondrial clearance in pancreatic cancer. First author DOI 10.1093/carcin/bgac060↗
  33. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Co-author DOI 10.1371/journal.pone.0267623↗
  34. Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer. First author DOI 10.1002/ags3.12447↗
  35. Practical significance of pancreatectomy with lymphadenectomy around the superior mesenteric artery for pancreatic cancer: comparison of prognosis after adjust… First author DOI 10.1007/s00423-021-02166-0↗
  36. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01964-2↗
  37. Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01986-w↗
  38. Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer. First author DOI 10.1111/cas.14921↗
  39. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. First author DOI 10.1111/cas.15123↗
  40. Splenic artery pseudoaneurysm following chemotherapy in a patient with pancreatic cancer: a case report. Co-author DOI 10.1007/s12328-020-01137-0↗
  41. Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells. Co-author DOI 10.1002/ags3.12025↗
  42. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Co-author DOI 10.18632/oncotarget.24577↗
  43. Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo. First author DOI 10.18632/oncotarget.24608↗
  44. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… Co-author DOI 10.21873/anticanres.13013↗
  45. Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation. Co-author DOI 10.1016/j.surg.2016.12.008↗
  46. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. Co-author DOI 10.21873/anticanres.11378↗
  47. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection. Co-author DOI 10.1007/s00268-016-3491-4↗
  48. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.034↗
  49. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. Co-author DOI 10.1016/j.jss.2016.06.047↗
  50. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Co-author DOI 10.1016/j.surg.2015.03.043↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 35 shared papers, 2021–2026 · strength 7.01
  2. Kenei Furukawa · 38 shared papers, 2014–2026 · strength 6.89
  3. Koichiro Haruki · 39 shared papers, 2014–2026 · strength 6.62
  4. Masashi Tsunematsu · 22 shared papers, 2022–2026 · strength 4.83
  5. Shinji Onda · 23 shared papers, 2021–2026 · strength 4.66
  6. Michinori Matsumoto · 17 shared papers, 2021–2026 · strength 3.63
  7. Ryoga Hamura · 21 shared papers, 2018–2026 · strength 3.59
  8. Takeshi Gocho · 19 shared papers, 2018–2026 · strength 3.55
  9. Mitsuru Yanagaki · 15 shared papers, 2021–2026 · strength 3.26
  10. Tomohiko Taniai · 13 shared papers, 2021–2026 · strength 2.56
  11. Norimitsu Okui · 10 shared papers, 2023–2026 · strength 2.30
  12. Tadashi Uwagawa · 12 shared papers, 2021–2026 · strength 2.12
  13. Yoshiaki Tanji · 9 shared papers, 2023–2026 · strength 2.06
  14. Taro Sakamoto · 10 shared papers, 2015–2026 · strength 1.77
  15. Tadashi Uwagawa · 11 shared papers, 2016–2025 · strength 1.45
  16. Kyohei Abe · 8 shared papers, 2021–2025 · strength 1.43
  17. Yosuke Igarashi · 6 shared papers, 2023–2026 · strength 1.39
  18. Hiroaki Shiba · 16 shared papers, 2014–2022 · strength 1.33
  19. Takashi Horiuchi · 14 shared papers, 2015–2022 · strength 1.23
  20. Katsuhiko K. Yanaga · 15 shared papers, 2014–2022 · strength 1.19
  21. Yuta Yamada · 4 shared papers, 2024–2026 · strength 1.01
  22. Nana Kimura · 4 shared papers, 2025 · strength 0.93
  23. Katsuhisa Hirano · 4 shared papers, 2025 · strength 0.93
  24. Tsutomu Fujii · 4 shared papers, 2025 · strength 0.93
  25. Mina Fukasawa · 3 shared papers, 2025 · strength 0.70

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.